Revance Therapeutics (RVNC) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 9, 2022 4:05 PM EDTPDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines Second quarter total revenue of $28.4 million, with RHA® Collection revenue of $25.5 million Aesthetic accounts across products and services totaled over 4,000 at quarter-end Revance launches RHA® Redensity for the treatment of moderate to severe perioral rhytids (lip lines) Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More
